Advisory Research Inc. Makes New Investment in Amgen Inc. $AMGN

Advisory Research Inc. purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 9,444 shares of the medical research company’s stock, valued at approximately $2,665,000.

Other large investors also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its stake in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. boosted its position in Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after acquiring an additional 5,853 shares during the last quarter. ABC Arbitrage SA grew its stake in shares of Amgen by 12.4% during the 2nd quarter. ABC Arbitrage SA now owns 5,756 shares of the medical research company’s stock worth $1,607,000 after acquiring an additional 634 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in shares of Amgen by 4.5% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 81,639 shares of the medical research company’s stock worth $22,794,000 after acquiring an additional 3,505 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $367.79 on Friday. The company has a fifty day moving average price of $356.96 and a two-hundred day moving average price of $324.63. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The stock has a market cap of $198.26 billion, a P/E ratio of 25.85, a P/E/G ratio of 3.75 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s payout ratio is presently 70.84%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: MariTide and osteoporosis drug sales cited as a key driver of recent investor enthusiasm; analysts/coverage note product momentum that helped push earlier gains. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Operational/production support: Rapid Micro Biosystems reported that Amgen expanded a global Growth Direct system rollout (multi‑system order), signaling investments in manufacturing capacity and process efficiency. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Positive Sentiment: Institutional buying/positioning: Amgen is highlighted as a holding in a large income fund, reflecting demand from dividend/income managers seeking defensive, high‑yield large caps. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Macro/sector support: Prominent market commentators have endorsed large‑cap biotech as resilient growth plays, which supports longer‑term investor interest. Josh Brown: Biotech growth stocks immune to disruption risk
• Neutral Sentiment: Company presentation: A recent Leerink Global Healthcare conference transcript provides updated management commentary — useful for gauging near‑term guidance and pipeline cadence but not an immediate catalyst by itself. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Valuation discussion: Coverage pieces assessing whether AMGN is mispriced highlight mixed returns vs. peers — useful context for investors but not a direct price mover. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest data appears to contain errors (reports show zero shares/NaN changes and a 0.0 days-to-cover figure); there’s no clear evidence of meaningful short pressure at present.
• Negative Sentiment: Analyst stance: Jefferies initiated coverage with a Hold recommendation, which can cap momentum relative to a Buy/Outperform narrative and may contribute to near‑term selling pressure. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation

Analysts Set New Price Targets

AMGN has been the topic of a number of research reports. Scotiabank began coverage on shares of Amgen in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price objective on the stock. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research note on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. Morgan Stanley increased their price objective on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus price target of $354.00.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.